Short-term efficacy of early percutaneous cholecystostomy for pancreatitis and factors associated with recurrence and mortality

Table 2 Pretreatment baseline data for both groups, n (%)

Variable	PC group (n = 54)	Conservative group (n = 29)	χ2 value	P value
Sex			0.774	0.379
Male	30 (55.6)	19 (65.5)
Female	24 (44.4)	10 (34.5)
Charlson comorbidities
Congestive heart failure	2 (3.7)	0	-	0.540
Diabetes mellitus (no comorbidities)	14 (25.9)	8 (27.6)	0.027	0.870
Solid tumors (no metastases)	3 (5.6)	0	-	0.548
Cerebrovascular disease	11 (20.4)	2 (6.9)	1.673	0.196
Use of antimicrobials
Cephalosporins	19 (35.2)	9 (31)	0.145	0.703
Nitroimidazoles	30 (55.6)	13 (44.8)	0.870	0.351
Growth inhibitors	34 (63)	17 (58.6)	0.150	0.698
Proton pump inhibitors	25 (46.3)	12 (41.4)	0.185	0.667
Combinations	40 (74.1)	22 (75.9)	0.032	0.858

PC: Percutaneous cholecystostomy.